Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 17/20 | 0.55 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.55 |
| ▸ | SLC5A1 | P13866 | 15/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4010805 | 1.00 | SLC5A2 (0.55) | SLC5A2SLC28A3SLC5A1POLBACHE | |
| SCHEMBL4001695 | 0.94 | SLC28A3 (0.59) | SLC5A2SLC28A3SLC5A1POLBACHE | |
| SCHEMBL4001687 | 0.94 | SLC28A3 (0.59) | SLC5A2SLC28A3SLC5A1POLBACHE | |
| SCHEMBL22717169 | 0.90 | SLC28A3 (0.51) | SLC5A2SLC28A3SLC5A1ACHE | |
| SCHEMBL4000120 | 0.88 | SLC5A2 (0.64) | SLC5A2SLC5A1POLBACHE | |
| SCHEMBL4000126 | 0.88 | SLC5A2 (0.64) | SLC5A2SLC5A1POLBACHE | |
| SCHEMBL17866099 | 0.87 | SLC28A3 (0.41) | SLC5A2SLC28A3SLC5A1 | |
| SCHEMBL4281449 | 0.84 | SLC5A2 (0.39) | SLC5A2SLC28A3SLC5A1 | |
| SCHEMBL4358723 | 0.82 | SLC5A2 (0.58) | SLC5A2SLC5A1 | |
| SCHEMBL4357913 | 0.81 | SLC28A3 (0.45) | SLC5A2SLC28A3SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951976-B2 | Progression inhibitor for disease attributed to abnormal accumulation of liver fat | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20090286751-A1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-7541341-B2 | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20080045466-A1 | Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-02-21 | — | — | US | disclosed |
| EP-1782828-A1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-05-09 | — | — | EP | disclosed |
| US-7129381-B2 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-10-31 | — | — | US | disclosed |
| US-7053060-B2 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-05-30 | — | — | US | disclosed |
| EP-1367060-B1 | GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2005-12-28 | — | — | EP | disclosed |
| US-20050113315-A1 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof | KISSEI PHARMACEUTICAL CO., LTD. | 2005-05-26 | — | — | US | disclosed |
| US-20050059614-A1 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof | KISSEI PHARMACEUTICAL CO., LTD. | 2005-03-17 | — | — | US | disclosed |
| US-20040138148-A1 | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| US-20040063170-A1 | Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1367060-A1 | GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-12-03 | — | — | EP | disclosed |
| EP-1344780-A1 | GLUCOPYRANOSYLOXYBENZYL BENZENE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES IN THE PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138148-A1 | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof | SLC5A2, SLC5A1, SLC2A1 | SLC5A2 1/4885SLC28A3 110/4885SLC5A1 2/4885 |
| US-20080045466-A1 | Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat | SLC10A1, SLC2A2, SLC2A1 | SLC5A2 10/4885SLC28A3 63/4885SLC5A1 12/4885 |
| US-20050113315-A1 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC28A3 162/4885SLC5A1 2/4885 |
| US-20090286751-A1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | FABP1, SLC2A1, SLC10A1 | SLC5A2 11/4885SLC28A3 59/4885SLC5A1 15/4885 |
| US-20050059614-A1 | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC28A3 176/4885SLC5A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.